Recent updates have progressed towards the quantitative estimation of biological factors, incorporating amyloid positivity and tau-PET spread, leading to a 4-stage model of AD progression (Jack Jr et al., 2024) Here we apply this staging model to the KARI dataset to provide insight into the composition of participants along these biological criteria. The gene discussed is MAPT; the disease is Alzheimer disease.